Experimental study finds AG1295 decreases proliferation and inflammation in corneal fibroblasts, suggesting therapeutic potential.
In patients with diabetes, fibroblasts may aggregate at sites of corneal injury, potentially promoting scar hyperplasia and reducing corneal transparency. These changes may be reversed by PDGFRβ phosphorylation inhibitors, suggesting new therapeutic avenues.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: